Search
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigationalFidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human coagulation FIX gene that was investigated as a potential treatment for hemophilia B. … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.
SJG-136
go.drugbank.com/drugs/DB11965InvestigationalSJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigational(+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Oprelvekin
go.drugbank.com/drugs/DB00038ApprovedInvestigationalWithdrawnOprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long.
mRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … more targeted immune response and the use of a significantly smaller amount of mRNA per dose.
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. … Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen.
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … [A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune
Synonyms: (T,G)-A-LMannitol
go.drugbank.com/drugs/DB00742ApprovedInvestigationalAs a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. … Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables.
Synonyms: D-Mannitol, D-(-)-MannitolInternational brands: Mannisol ADocetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigationalDocetaxel is a complex diterpenoid molecule and a semisynthetic analogue of [paclitaxel]. … [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: DOCETAXEL DONG-A, DOCETAXEL PHARMAKI GENERICS